Suppr超能文献

在2型糖尿病中,纤溶酶原激活物抑制剂-1(PAI-1)活性与低密度脂蛋白(LDL)颗粒大小呈负相关,而纤维蛋白原或血管性血友病因子则不然。

PAI-1 activity, but not fibrinogen or von Willebrand factor, is inversely related to LDL particle size in type 2 diabetes.

作者信息

Mertens Ilse, Lemieux Isabelle, Verrijken An, Després Jean-Pierre, Van Gaal Luc F

机构信息

Department of Diabetology, Metabolism and Clinical Nutrition, Faculty of Medicine, Antwerp University Hospital, Antwerp, Belgium.

出版信息

Diabetes Metab Res Rev. 2008 Feb;24(2):141-7. doi: 10.1002/dmrr.779.

Abstract

BACKGROUND

Levels of fibrinogen, von Willebrand factor (vWF) and plasminogen activator inhibitor-1 (PAI-1) have been associated with small low-density lipoprotein (LDL) particles. However, it is not clear whether these associations are independent of visceral adiposity or other components of the metabolic syndrome such as triglycerides or insulin resistance.

METHODS

Visceral adipose tissue (VAT; CT-scan), fibrinogen, von Willebrand factor antigen (vWF:Ag), PAI-1 activity and different metabolic parameters such as total cholesterol (chol), HDL-chol, triglycerides, insulin resistance (homeostasis model assessment; HOMA-IR) were determined in 41 women and 78 men with type 2 diabetes. LDL particle size was assessed by polyacrylamide gradient gel electrophoresis.

RESULTS

PAI-1 activity was inversely related to LDL particle size after adjustment for age and body mass index (BMI) (r=-0.28; p=0.006) or age and VAT (r=-0.26; p=0.01), but not after adjustment for age and HOMA-IR (r=-0.15; p=0.148) or age and triglycerides (r=-0.04; p=0.679). In multiple regression analysis, LDL particle size did not independently determine PAI-1 activity levels. Fibrinogen and vWF:Ag did not seem to be related to LDL size.

CONCLUSIONS

PAI-1 activity levels, in contrast to fibrinogen and vWF:Ag, seem to be related to the small LDL phenotype in patients with type 2 diabetes. However, this relationship was not independent of insulin resistance or triglycerides.

摘要

背景

纤维蛋白原、血管性血友病因子(vWF)和纤溶酶原激活物抑制剂-1(PAI-1)的水平与小而密低密度脂蛋白(LDL)颗粒有关。然而,尚不清楚这些关联是否独立于内脏脂肪或代谢综合征的其他成分,如甘油三酯或胰岛素抵抗。

方法

对41名女性和78名2型糖尿病男性患者测定内脏脂肪组织(VAT;CT扫描)、纤维蛋白原、血管性血友病因子抗原(vWF:Ag)、PAI-1活性以及不同的代谢参数,如总胆固醇(chol)、高密度脂蛋白胆固醇(HDL-chol)、甘油三酯、胰岛素抵抗(稳态模型评估;HOMA-IR)。通过聚丙烯酰胺梯度凝胶电泳评估LDL颗粒大小。

结果

在校正年龄和体重指数(BMI)(r=-0.28;p=0.006)或年龄和VAT(r=-0.26;p=0.01)后,PAI-1活性与LDL颗粒大小呈负相关,但在校正年龄和HOMA-IR(r=-0.15;p=0.148)或年龄和甘油三酯(r=-0.04;p=0.679)后则无相关性。在多元回归分析中,LDL颗粒大小不能独立决定PAI-1活性水平。纤维蛋白原和vWF:Ag似乎与LDL大小无关。

结论

与纤维蛋白原和vWF:Ag不同,PAI-1活性水平似乎与2型糖尿病患者的小LDL表型有关。然而,这种关系并非独立于胰岛素抵抗或甘油三酯。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验